首页 | 官方网站   微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   232927篇
  免费   15311篇
  国内免费   983篇
医药卫生   249221篇
  2023年   1226篇
  2022年   897篇
  2021年   5325篇
  2020年   3044篇
  2019年   5054篇
  2018年   6050篇
  2017年   4440篇
  2016年   4847篇
  2015年   5730篇
  2014年   8346篇
  2013年   11246篇
  2012年   17278篇
  2011年   18009篇
  2010年   10068篇
  2009年   9311篇
  2008年   15861篇
  2007年   16654篇
  2006年   16199篇
  2005年   16055篇
  2004年   15102篇
  2003年   13788篇
  2002年   13189篇
  2001年   1936篇
  2000年   1438篇
  1999年   2007篇
  1998年   2787篇
  1997年   2213篇
  1996年   1924篇
  1995年   1763篇
  1994年   1528篇
  1993年   1457篇
  1992年   937篇
  1991年   916篇
  1990年   768篇
  1989年   724篇
  1988年   666篇
  1987年   599篇
  1986年   622篇
  1985年   672篇
  1984年   886篇
  1983年   768篇
  1982年   1011篇
  1981年   940篇
  1980年   823篇
  1979年   444篇
  1978年   496篇
  1977年   430篇
  1976年   400篇
  1975年   299篇
  1974年   304篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
School Mental Health - A dual approach to mental health in schools has been widely defended, where the assessment of psychological distress and the examination of strengths/well-being are two...  相似文献   
12.
13.
Non-clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non-clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first- and second-line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC-Registry), 99 patients with papillary mRCC treated with systemic first-line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first-line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression-free survival from start of first-line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow-up, and 9% were alive at the end of the individual 3-year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real-world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC.  相似文献   
14.
15.
This article describes a case of anaphylaxis secondary to chlorhexidine during urethral catheterisation. Despite little evidence for the use of antiseptic lubricants in preventing catheter-associated urinary tract infections, the distribution and use of such products continues to be widespread. Chlorhexidine-free lubricating gel is widely available and should be used for urological procedures wherever possible.  相似文献   
16.
17.
18.
19.
20.
European Journal of Orthopaedic Surgery & Traumatology - The goals of this study were to compare patient satisfaction and wound-related complications in patients receiving 2-octyl cyanoacrylate...  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号